Since not all relevant molecular mutations are reported for the cell lines used here, we performed Next Generation Sequencing (Illumina, True Sight Tumor 15 Panel) to complete the cell line information given in Table 2, which we further expanded with the methylation information from in-house validated assays targeting the promoter regions of CDH1, CDKN2Ap16, RASSF1A, TERT, and WT1. This evidence concerns the gene WT1 and neoplasm.